Vaxil Bio Ltd. (VXL.V)
| Previous Close | 0.0300 |
| Open | 0.0300 |
| Bid | 0.0250 x 0 |
| Ask | 0.0300 x 0 |
| Day's Range | 0.0250 - 0.0300 |
| 52 Week Range | 0.0250 - 0.1200 |
| Volume | |
| Avg. Volume | 66,135 |
| Market Cap | 4.109M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0060 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- GlobeNewswire
Vaxil Provides Update on Research Activities
Not for distribution by US newswire or in United States NESS-ZIONA, Israel, March 07, 2022 (GLOBE NEWSWIRE) -- VAXIL BIO LTD. (“Vaxil” or the “Company”) (TSX VENTURE: VXL), an innovative immunotherapy biotech company is pleased to provide an update on its research activities. Vaxil previously reported therapeutic success of P-Esbp-DOX, a novel anti-cancer drug, when tested in vivo in a mouse model of aggressive liver metastasis of colorectal cancer (CRC). P-Esbp-DOX was developed by Prof. Ayelet
- GlobeNewswire
Vaxil’s Annual and Special Shareholders Meeting
Not for distribution by US newswire or in United States NESS-ZIONA, Israel, Feb. 08, 2022 (GLOBE NEWSWIRE) -- VAXIL BIO LTD. (“Vaxil” or the “Company”) (TSX VENTURE: VXL), an innovative immunotherapy biotech company specializing in cancer and infectious diseases, announces that at the Company's Annual and Special General Meeting, held virtually, on February 7, 2022, all resolutions were duly passed by shareholders. ABOUT VAXIL Vaxil is an Israeli immunotherapy biotech company focused on its nove
